Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Impact of DHT on Swallowing Physiology in HNCa Patients
Head/Neck
Head/Neck
Head/Neck
N/A
Topf, Michael
VICCHN2102
Blood based biomarkers for minimal residual disease detection in Pediatric Sarcomas
Multiple Cancer Types
Pediatrics,
Sarcoma
N/A
Borinstein, Scott
VICCPED2160
Open-Label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years with Haemophilia A or B with or without Inhibitors
Benign Hematologic
Benign Hematologic
Benign Hematologic
III
Wheeler, Allison
VICCNCBH21108
Laryngeal Cancer Treatment Decision-Making: A Conjoint Analysis of Post-Treatment Priorities
Not Available
N/A
Topf, Michael
VICCHN2201
CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan.
Multiple Cancer Types
Pediatrics,
Sarcoma
N/A
Friedman, Debra
VICCPED2222
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Multiple Cancer Types
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Multiple Myeloma,
Phase I
I
Baljevic, Muhamed
NCT05338775
VICCHEMP2253
RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors
Phase I
Phase I
RBS2418 (investigational product) is a specific immune modulator, working through
ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor
immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine
monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine
production in the tumors. RBS2418 has the potential to be an important therapeutic option for
subjects both as monotherapy and in combination with checkpoint blockade. This study is an
open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in
combination with pembrolizumab or as a monotherapy in subjects with advanced unresectable,
recurrent or metastatic tumors.
ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor
immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine
monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine
production in the tumors. RBS2418 has the potential to be an important therapeutic option for
subjects both as monotherapy and in combination with checkpoint blockade. This study is an
open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in
combination with pembrolizumab or as a monotherapy in subjects with advanced unresectable,
recurrent or metastatic tumors.
Phase I
I
Berlin, Jordan
NCT05270213
VICCPHI2289
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Multiple Cancer Types
Clinical study to investigate the efficacy and safety of savolitinib in combination with
osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated,
MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed
on treatment with Osimertinib.
osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated,
MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed
on treatment with Osimertinib.
Lung,
Non Small Cell
III
Iams, Wade
NCT05261399
VICCTHO2219
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Lung
Lung
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international
study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154)
compared with durvalumab plus placebo in adults with locally advanced (Stage III),
unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154)
compared with durvalumab plus placebo in adults with locally advanced (Stage III),
unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Lung
III
Whitaker, Ryan
NCT05211895
VICCTHO2297
